Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATATE PET/CT for Neuroendocrine Tumors
NCT01967537Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga 68 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Primary endpoint: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan up to 5 years. Started Oct 2013; status: completed.
02
Drugs
gallium ga 68 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01967537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01967537.